DailySand tracks tirzepatide across AI, semiconductor infrastructure, capital markets, and critical minerals supply chains. Below are curated source items and daily digests where tirzepatide appears in today's cross-sector intelligence briefing.
1 item across 1 digest
Eli Lilly's combo obesity treatment combining eloralintide with tirzepatide showed positive weight-loss results in mid-stage trials, with Phase 3 trials planned for end of year. Success in obesity therapeutics expands Lilly's GLP-1 portfolio and addresses a large market opportunity.
Read original →
DailySand